Phase 2 N=64 A Study of the Response to AG-86893 in Patients With Pterygium Hyperemia
Pterygium
Primary: Change From Baseline in Overall Conjunctival Hyperemia Score — -0.056; -0.330; -0.352 score on a scale — p=0.218
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=18 Safety and Tolerability Study for Age-Related Macular Degeneration
Neovascular Age-Related Macular Degeneration
Primary: Mean Change in Central Retinal Subfield Thickness as Measured by Optical Coherence Tomography (OCT) at Week 24 From Baseline — -98; -66; -180.8 Microns
Phase 2 N=40 Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Fallopian Tube Clear Cell Adenocarcinoma · Fallopian Tube Endometrioid Adenocarcinoma · Fallopian Tube Mucinous Adenocarcinoma
Primary: Incidence of Adverse Events Assessed by Common Terminology Criteria for Adverse Events — 1; 9; 20; 9 Participants
Phase 2 N=610 BI 425809 in Patients With Cognitive Impairment Due to Alzheimer's Disease.
Alzheimer Disease
Primary: Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale 11 Item (ADAS-Cog11) Total Score After 12 Weeks of Treatment — 0.026; 0.175; 0.699…
Phase 2 N=47 A Randomized Study to Assess the Safety of GRF6019 Infusions in Subjects With Mild to Moderate Alzheimer's Disease
Alzheimer Disease · Mild to Moderate Alzheimer Disease
Primary: Frequency of Treatment-emergent Adverse Events (Safety) — 18; 20 Participants
Phase 2 N=109 Study of Enzastaurin Versus Placebo in the Treatment of Patients With Brain Metastases of Lung Cancer, After Whole Brain Radiation Therapy
Non Small Cell Lung Cancer · Small Cell Lung Cancer
Primary: Time to Progression of Brain Metastases — 6.9; 4.9 months
Phase 2 N=29 HSCT For Patients With High Risk Hemoglobinopathies Using Reduced Intensity
Sickle Cell Disease · Beta Thalassemia-Major
Primary: Number of Participants With Sustained Cell Engraftment of Donor Cells — 29 Participants
Phase 2 N=64 Lenalidomide, Thalidomide and Dexamethasone in Treating Participants With Relapsed or Refractory Multiple Myeloma
Recurrent Plasma Cell Myeloma · Refractory Plasma Cell Myeloma
Primary: Number of Participants With Dose Limitations Toxicities of the Combination of Lenalidomide and Thalidomide and Dexamethasone (LTD) in Patients With Relapsed/Refractory…
Phase 2 N=30 Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.
Covid19 · SARS-CoV-2 PNEUMONIA · COVID-19
Primary: Number of Participants With Non-serious and Serious Adverse Events During Trial — 0; 0; 0; 0 Participants
Phase 2 N=29 Ofatumumab/Methylprednisolone and Ofatumumab/Lenalidomide for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Chronic Lymphocytic Leukemia · Small Lymphocytic Lymphoma
Primary: Objective Response Rate (ORR) — 48.3 percentage of participants
Phase 2 N=5 Vaccine for Patients With Newly Diagnosed or Recurrent Low-Grade Glioma
Adult Diffuse Astrocytoma · Adult Mixed Glioma · Adult Oligodendroglioma
Primary: Progression-free Survival (PFS) of Low Grade Glioma Patients Treated With Autologous Dendritic Cells Pulsed With Autologous Tumor Lysate — 0; 1; 1; 1 participants
Phase 2 N=22 Milk Thistle in Trichotillomania in Children and Adults
Trichotillomania · Hair Pulling Disorder
Primary: Change in NIMH Trichotillomania Severity Scale (NIMH-TSS) Scores — 9.4; 9.4; 6.3; 7.4 score on a scale
Phase 2 N=10 Assess the Feasibility and Efficacy of the CollaRx® Bupivacaine Implant Laparoscopic Inguinal or Umbilical Herniorrhaphy
Hernia · Postoperative Pain
Primary: Total Use of Opioid Analgesia - Morphine Equivalence (mg) — 19.3 Morphine Equivalence (mg)
Phase 2 N=393 Safety, Tolerability, and Immunogenicity Study of Homologous Ad26 Mosaic Vector Vaccine Regimens or Heterologous Ad26 Mosaic and MVA Mosaic Vector Vaccine Regimens With Glycoprotein 140 (gp140) for Human Immunodeficiency Virus (HIV) Prevention
Healthy
Primary: Percentage of Participants With Solicited Local Adverse Events (AEs) Post Vaccination — 88.0; 83.7; 75.5; 77.1 percentage of participants
Phase 2 N=27 Efficacy and Safety of the CollaRx Bupivacaine Implant Compared to the ON-Q Painbuster Following Abdominal Hysterectomy
Pain, Postoperative
Primary: Total Amount of Opioid Rescue Analgesia Used — 46.85; 67.03 Morphine Milligrams